GPhA Asks FDA To Create Task Force On Generic Biopharmaceuticals
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency should abandon its “arbitrator” role in the face of the brand industry’s continued reluctance to discuss a path forward, GPhA maintains. FDA should put together an analysis of the issues to be presented at an upcoming FDA/DIA meeting.